ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0509 • ACR Convergence 2024

    Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021

    Lydia Lee1, Jeffrey Sparks2, Priyanka Yalamanchili1, Daniel B. Horton3, Zeba Khan4, Joseph Barone4 and Chintan Dave5, 1Rutgers University, New Brunswick, NJ, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 3Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 4Rutgers University, New Brunswick, 5Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ

    Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
  • Abstract Number: 0526 • ACR Convergence 2024

    Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study

    Narendra Maharaj1, Dharma rao Uppada2, Naveen Reddy MAREDDY1, Pramod Reddy Pundra1, Anastas Batalov3, Delina Ivanova4, nedyalka staykova5, Asta Baranauskaite6 and Laila Hassan7, 1Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, 2Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, 3Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, 4Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, 5Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, 6Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, 711914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX

    Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
  • Abstract Number: 0797 • ACR Convergence 2024

    Associations Between Discordance of Disease Activity Indices and Quantitative Sensory Testing Measures of Nociplastic Pain in Patients with Early Rheumatoid Arthritis

    Clarice Lin1, Burcu Aydemir1, Jing Song2, Lutfiyya Muhammad3, Tuhina Neogi4, Wendy Marder5, Clifton Bingham6, Marcy Bolster7, Daniel Clauw8, Dorothy Dunlop9 and Yvonne Lee1, 1Northwestern University, Chicago, IL, 2Northwestern University, Worthington, MN, 3Northwestern Feinberg School of Medicine, Chicago, IL, 4Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 5University of Michigan, Ann Arbor, MI, 6Johns Hopkins University, Baltimore, MD, 7Massachusetts General Hospital, Boston, MA, 8University of Michigan, Whitmore Lake, MI, 9Northwestern University, New Haven, CT

    Background/Purpose: Approximately one-third of patients with rheumatoid arthritis (RA) experience nociplastic pain, a type of pain that occurs due to abnormalities in the way the…
  • Abstract Number: 0886 • ACR Convergence 2024

    A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis

    Chenxi Zhu1, Siyu He2, Yi Liu3, Rui Sun1 and Yi Zhao4, 1Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), 2West China Hospital Sichuan University, chengdu, China (People's Republic), 3Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, 4Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…
  • Abstract Number: 0941 • ACR Convergence 2024

    DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways

    Michal Segal Salto1, Rebecca Ross2, Steven Ferrara3, Kelvin Chan4, Elvira haimov5, Francesco Del Galdo6 and Kulveer Mankia6, 1DeepCure Inc., Tel Aviv, Israel, 2Medicine and Health, University of Leeds, Leeds, United Kingdom, 3DeepCure Inc., Boston, MA, 4DeepCure Inc., Texas, NV, 5DeepCure Inc., Los Angeles, CA, 6University of Leeds, Leeds, United Kingdom

    Background/Purpose: Bromodomain and Extra-Terminal domain (BET) family proteins (BRD2, BRD3, BRD4, and BRDT) control the transcription of a wide range of proinflammatory and immunoregulatory genes.…
  • Abstract Number: 1006 • ACR Convergence 2024

    Associations Between Rheumatic Diseases and Mental Health Disorders

    Thoai Vu, Sivam Bhatt and Janet Lewis, University of Virginia, Charlottesville, VA

    Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…
  • Abstract Number: 1048 • ACR Convergence 2024

    Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

    Karina Palomo-Arnaud1, Gabriel Figueroa-Parra2, Angel Kevin Garza-Elizondo1, Margarita Isabel Alarcon Jarquin3, Jesus Cardenas-de la Garza4, Dionicio Galarza-Delgado5 and Janett Riega Torres2, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, 4Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 5UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Oral manifestations, especially periodontitis and tooth loss, are highly prevalent in patients with rheumatic diseases. Sjogren’s syndrome (SS), rheumatoid arthritis (RA), and systemic lupus…
  • Abstract Number: 1324 • ACR Convergence 2024

    Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations

    Shirish Dubey1, Abhinav Peddasomayajula2, Damodar Makkuni3, Anupama Nandagudi4, Win Win Maw5 and Gouri M Koduri6, 1Oxford University Hospitals NHS FT, Oxford, United Kingdom, 2Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, 3James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, 4MSEFT, Basildon, United Kingdom, 5Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, 6Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom

    Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces…
  • Abstract Number: 1341 • ACR Convergence 2024

    Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis

    Santiago Dans Caballero1, Marta Rojas Giménez2, Clementina López Medina3, Andrea Cid Chaves2, Mónica Rico-Muñoz3, mitndbaim aelohim parra Moreno2 and Alejandro Escudero-Contreras4, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2Reina Sofia University Hospital, Cordoba, Andalucia, Spain, 3Reina Sofia University Hospital, Cordoba, Spain, 4Reina Sofia University Hospital, Córdoba, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
  • Abstract Number: 1357 • ACR Convergence 2024

    Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial

    Sho Fukui1, Lesley Inker2, Leah Santacroce3, Jon Giles4, Katherine Liao3, Joan Bathon5 and Daniel Solomon6, 1Brigham and Women's Hospital, Brookline, MA, 2Tufts Medical Center, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Cedars Sinai Medical Center, Los Angeles, CA, 5Columbia University, NEW YORK, NY, 6Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Glomerular filtration rate (GFR) is difficult to measure in patients with RA since creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate GFR due to…
  • Abstract Number: 1373 • ACR Convergence 2024

    The Effect of Methotrexate on Lipid and Apolipoprotein Levels in RA Goes Hand-in-hand with EULAR Response

    Varun Dhir1, Chandra Bhushan Prasad2, Siddharth Jain3, shankar naidu4, Aman Sharma5, Shefali Sharma6, Indu Verma7 and sanjay jain8, 1PGIMER, CHD, INDIA, CHANDIGARH, India, 2Healthway Hospital, Goa, India, Zuarinagar, Goa, India, 3All India Institute of Medical Sciences, New Delhi, Delhi, Delhi, India, 4PGIMER, Chandigarh, India, Chandigarh, India, 5PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 6Government, Chandigarh, Chandigarh, India, 7PGIMER, Chandigarh, India, 8PGIMER, Chandigarh, Chandigarh, India

    Background/Purpose: Methotrexate improves cardiovascular risk in autoimmune inflammatory diseases like RA, and has been shown to suppress inflammation and increase lipid levels. However, it is…
  • Abstract Number: 1390 • ACR Convergence 2024

    One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)

    Luis Gomez-Lechon Quiros1, José Miguel Sequí-Sabater2, Amalia Rueda3, Costas Torrijo Nerea4, Carlos Valera-Ribera5, Juan Miguel López-Gómez6 and Antonio Alvarez-Cienfuegos7, 1Hospital Francesc de Borja, Valéncia, Spain, 2La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, 3Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 4Generalitat valenciana, Valencia, Spain, 5Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, 6Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, 7Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
  • Abstract Number: 1648 • ACR Convergence 2024

    In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells

    Giulia Frazzei1, Ana Merino Vico2, Jan Piet van Hamburg2, Ronald Van Vollenhoven3 and Sander Tas4, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
  • Abstract Number: 1719 • ACR Convergence 2024

    Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study

    Beth Wallace1, Yuqing Gao2, H. Myra Kim3, Bryant England4, Sauer brian5, grant Cannon6, Punyasha Roul7, Ted Mikuls4, Shirley Cohen-Mekelburg8, Daniel Clauw9, Wyndy Wiitala2, Rodney Hayward10, Jeremy Sussman11 and Akbar Waljee11, 1Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 2Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3University of Michigan School of Public Health, Ann Arbor, MI, 4University of Nebraska Medical Center, Omaha, NE, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7UNMC, Omaha, NE, 8University of Michigan Department of Internal Medicine, Division of Gastroenterology, Ann Arbor, MI, 9University of Michigan, Whitmore Lake, MI, 10Department of Internal Medicine, University of Michigan; Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, 11Internal Medicine and Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…
  • Abstract Number: 1850 • ACR Convergence 2024

    Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients

    Samuel Bitoun1, Marie Naigeon2, Matthieu Roulleaux- Dugage2, Caroline De Oliveira2, Caroline Berthot2, Xavier Mariette3, Gaetane Nocturne3 and Nathalie Chaput-Gras2, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, 3Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology